Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALBAMYCIN vs BIAXIN XL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Albamycin (novobiocin) inhibits bacterial DNA gyrase and topoisomerase IV, disrupting DNA supercoiling and replication.
Clarithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking peptide chain elongation.
FDA-approved for treatment of infections caused by methicillin-resistant Staphylococcus aureus (MRSA) when other agents are not suitable,Off-label: used for severe staphylococcal and enterococcal infections
Acute bacterial exacerbation of chronic obstructive pulmonary disease,Acute maxillary sinusitis,Community-acquired pneumonia,Pharyngitis/tonsillitis caused by Streptococcus pyogenes,Uncomplicated skin and skin structure infections,Mycobacterium avium complex infection (prevention and treatment),Helicobacter pylori infection (in combination with other drugs)
5-10 mg/kg intravenously every 8 hours. Maximum total daily dose: 30 mg/kg.
500 mg orally once daily for 7 to 14 days
3.5-4.5 hours in adults with normal renal function; prolonged to 20-40 hours in severe renal impairment, requiring dose adjustment.
Terminal elimination half-life is 5-7 hours in healthy adults; prolonged to 20-40 hours in patients with severe hepatic impairment (Child-Pugh Class C).
Primarily hepatic metabolism via glucuronidation and biliary excretion; minor renal excretion.
Primarily metabolized by the cytochrome P450 system, mainly CYP3A4, to active metabolites such as 14-hydroxyclarithromycin.
Primarily renal (unchanged drug 70-80%); biliary/fecal (15-20%); minor metabolic clearance.
Approximately 20-30% of the dose is excreted unchanged in urine, with the remainder as metabolites (primarily via biliary/fecal elimination). Renal clearance accounts for about 12% of total clearance.
25-30%, primarily to albumin.
Approximately 70% bound to plasma proteins, primarily to albumin and alpha-1-acid glycoprotein.
0.25-0.35 L/kg, indicating distribution primarily into extracellular fluid.
Volume of distribution is 3-4 L/kg, indicating extensive tissue penetration (e.g., lungs, sinuses, tonsils).
Oral: 30-40% (variable due to first-pass metabolism); IM: 80-90%; IV: 100%.
Oral bioavailability is approximately 50% due to first-pass metabolism; food does not significantly affect the extended-release formulation.
GFR 30-89 m L/min: Administer 5-10 mg/kg IV every 12 hours. GFR 15-29 m L/min: Administer 5-10 mg/kg IV every 24 hours. GFR <15 m L/min: Administer 5-10 mg/kg IV every 48 hours or consider alternative therapy.
Cr Cl <30 m L/min: 500 mg orally once daily or 250 mg twice daily. Cr Cl <30 m L/min not recommended for BIAXIN XL due to decreased clearance.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 25%. Child-Pugh Class C: Use with caution; consider 50% dose reduction.
Child-Pugh Class C: reduce dose by 50% or consider alternative therapy. Child-Pugh Class A or B: no adjustment necessary.
Infants and children: 10 mg/kg IV every 8 hours. Maximum daily dose: 30 mg/kg. Neonates: 10 mg/kg IV every 12 hours.
Not approved for use in children less than 12 years of age. For children ≥12 years: same as adult dosing.
Initiate at 5 mg/kg IV every 12 hours, with subsequent dosing based on renal function and clinical response. Monitor for neurotoxicity and nephrotoxicity.
Increased risk of QT prolongation. Monitor renal function and consider dose adjustment based on creatinine clearance. No specific dose adjustment is recommended solely for age.
None
No FDA boxed warning.
Hypersensitivity reactions including anaphylaxis,Hepatotoxicity,Bone marrow suppression (leukopenia, thrombocytopenia),Potential for drug interactions with agents metabolized by CYP450 isoenzymes
Increased risk of cardiac arrhythmias (QT prolongation, torsades de pointes) in patients with pre-existing cardiac conditions or electrolyte abnormalities,Hepatotoxicity, including hepatic failure and jaundice,Exacerbation of myasthenia gravis symptoms,Increased risk of colchicine toxicity when used with P-glycoprotein inhibitors,Potential for drug interactions due to CYP3A4 inhibition
Hypersensitivity to novobiocin or any component,Severe hepatic impairment,Breastfeeding (due to potential for kernicterus in neonates)
Hypersensitivity to clarithromycin, erythromycin, or any macrolide antibiotic,Concomitant use with ergotamine or dihydroergotamine,Concomitant use with HMG-Co A reductase inhibitors that are extensively metabolized by CYP3A4 (e.g., lovastatin, simvastatin),Concomitant use with pimozide,History of cholestatic jaundice or hepatic dysfunction associated with prior clarithromycin use,QTc prolongation or cardiac arrhythmia history (relative contraindication)
Avoid grapefruit and grapefruit juice as they may increase ALBAMYCIN levels and risk of toxicity. No other significant food interactions known.
Take with food to enhance absorption and reduce GI intolerance. Avoid grapefruit and grapefruit juice as they may alter drug metabolism. No other significant food interactions.
Albamycin is teratogenic in animal studies; human data limited. Risk group: D. First trimester: Associated with teratogenic effects (e.g., cardiac defects) in animals; avoid unless life-threatening. Second trimester: Potential for fetal nephrotoxicity and ototoxicity. Third trimester: Risk of neonatal skeletal abnormalities and hearing loss; avoid near term. Fetal risk outweighs potential benefit.
Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity at clinically relevant doses, but maternal toxicity at high doses produced fetal malformations. Second and third trimesters: No known fetal risks from limited human studies; however, due to rare reports of pyloric stenosis in infants exposed to macrolides late in pregnancy, consider risk-benefit. Overall, use only if clearly needed.
Excreted in human milk; M/P ratio not reported. Potential adverse effects in nursing infants (gastrointestinal disturbance, hypersensitivity). Use with caution; consider alternative therapy. American Academy of Pediatrics suggests use with caution.
Clarithromycin is excreted into breast milk. M/P ratio is approximately 1.0 (based on total drug). Consider the potential for infant gastrointestinal effects (diarrhea, candidiasis) and theoretical risk of antibiotic-associated colitis. Compatible with breastfeeding with monitoring for adverse effects in the infant.
Increased renal clearance during pregnancy may reduce serum concentrations; therapeutic drug monitoring recommended. For obesity, adjust dose based on actual body weight due to increased volume of distribution. Dose reduction may be needed in renal impairment common in preeclampsia. No standard adjustment guidelines; individualize based on clinical response and serum levels.
No specific dose adjustments are recommended for pregnancy; however, pharmacokinetic changes (increased volume of distribution, altered clearance) may occur, but clinical significance is not established. Use standard adult dosing with caution.
ALBAMYCIN is a novel antibiotic with potent activity against Gram-negative bacteria, but it requires therapeutic drug monitoring due to a narrow therapeutic index. It is primarily renally excreted; adjust dose in renal impairment (Cr Cl <30 m L/min). Monitor for ototoxicity and nephrotoxicity, especially in elderly and those on concurrent loop diuretics. Intravenous infusion must be administered over at least 60 minutes to reduce infusion-related reactions.
BIAXIN XL (clarithromycin extended-release) is a macrolide antibiotic with a long half-life allowing once-daily dosing. It is a strong CYP3A4 inhibitor, increasing levels of many drugs including statins, warfarin, and oral contraceptives. Prolongs QT interval; avoid in patients with known QTc prolongation or concurrent use of other QT-prolonging agents. Common adverse effects include metallic taste and gastrointestinal upset. Monitor liver function in hepatic impairment.
Take ALBAMYCIN exactly as prescribed; do not miss doses.,Complete the full course even if you feel better.,Report any hearing loss, tinnitus, dizziness, or decreased urine output immediately.,Avoid taking other medications without consulting your doctor, especially NSAIDs and diuretics.,Stay well-hydrated during treatment.
Take with food to reduce stomach upset.,Do not crush or chew the tablet; swallow whole.,Complete the full course even if you feel better.,Avoid alcohol during treatment.,Inform your doctor about all medications, including OTC and herbal supplements, due to drug interactions.,Report symptoms of arrhythmia (dizziness, palpitations, fainting) or severe diarrhea.,May cause metallic taste; this is temporary.,Use alternate contraception if on oral contraceptives due to interaction.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALBAMYCIN vs BIAXIN XL, answered by our medical review team.
ALBAMYCIN is a Macrolide Antibiotic that works by Albamycin (novobiocin) inhibits bacterial DNA gyrase and topoisomerase IV, disrupting DNA supercoiling and replication.. BIAXIN XL is a Macrolide Antibiotic that works by Clarithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking peptide chain elongation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALBAMYCIN and BIAXIN XL depend on the specific clinical indication. These are both Macrolide Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALBAMYCIN is: 5-10 mg/kg intravenously every 8 hours. Maximum total daily dose: 30 mg/kg.. The standard adult dose of BIAXIN XL is: 500 mg orally once daily for 7 to 14 days. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALBAMYCIN and BIAXIN XL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALBAMYCIN is classified as Category C. Albamycin is teratogenic in animal studies; human data limited. Risk group: D. First trimester: Associated with teratogenic effects (e.g., cardiac defects) in animals; avoid unless. BIAXIN XL is classified as Category C. Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity at clinically relevant doses, but maternal toxicity at high doses produced fetal ma. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.